Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited
Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.
Johnson & Johnson (NYSE:JNJ) Faces Shareholder Activism Over Human Rights and Executive Pay Proposals
Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...
pharmaphorum23h
After a nay from NICE, Scotland says aye to J&J’s Spravato
NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England.